Evidence map›Paper›PMID 40767451›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025

Asymmetric Total Synthesis of (-)-Glycybridin B, a Pharmacophore Screened Candidate for Tubulin Binding.

Alice Maiocchi, Maxim Shevelev, Zlata Boiarska, Juan Estévez-Gallego, Francesca Bonato, Paolo Orlando, Alessandra Chinosi, Emanuele Marcone, Andrea Citarella, Dragos Horvath and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alice MaiocchiDepartment of Chemistry, University of Milan, -, Milan, 20133, Italy.
Maxim ShevelevLaboratory of Chemoinformatics, University of Strasbourg, Strasbourg, 67081, France.
Zlata BoiarskaDepartment of Chemistry, University of Milan, -, Milan, 20133, Italy.
Juan Estévez-GallegoPSI Center for Life Sciences, Villigen PSI, 5232, Switzerland.
Francesca BonatoDepartment of Chemistry, University of Milan, -, Milan, 20133, Italy.
Paolo OrlandoDepartment of Chemistry, University of Milan, -, Milan, 20133, Italy.
Alessandra ChinosiDepartment of Chemistry, University of Milan, -, Milan, 20133, Italy.
Emanuele MarconeDepartment of Chemistry, University of Milan, -, Milan, 20133, Italy.
Andrea CitarellaDepartment of Chemistry, University of Milan, -, Milan, 20133, Italy.
Dragos HorvathLaboratory of Chemoinformatics, University of Strasbourg, Strasbourg, 67081, France.
Michel O SteinmetzPSI Center for Life Sciences, Villigen PSI, 5232, Switzerland.
Andrea E ProtaPSI Center for Life Sciences, Villigen PSI, 5232, Switzerland.
Alexandre VarnekLaboratory of Chemoinformatics, University of Strasbourg, Strasbourg, 67081, France.
Valerio FasanoDepartment of Chemistry, University of Milan, -, Milan, 20133, Italy.
Daniele PassarellaDepartment of Chemistry, University of Milan, -, Milan, 20133, Italy.ORCID https://orcid.org/0000-0001-6180-9581

Funding

H2020 Marie Skłodowska-Curie Actions 860070 TUBINTRAIN
6 · The paper itself

Abstract

Microtubule-targeting agents (MTAs) represent a pivotal class of therapeutic compounds designed to disrupt microtubule dynamics, leading to cell cycle arrest and apoptosis in malignant cells. Nevertheless, their off-target effects on healthy, rapidly dividing cells result in significant neurotoxicity and myelosuppression. Ongoing research aims to enhance their specificity and identify novel active scaffolds to minimize adverse effects and fight drug resistance. Searching for new potential tubulin binders with a pharmacophore screening method, we identified glycybridin B as a promising natural product. Here, we report the first total synthesis of this compound via a five-step route, involving a key chalcone intermediate, along with its biological evaluation.

Indexed as

TubulinTubulin ModulatorsApoptosisHumansMicrotubulesPharmacophoreProtein BindingStereoisomerismTubulinTubulin Modulatorsglycybridin Bnatural productstotal synthesistubulinvirtual screening

Identifiers

PMID40767451
PMCPMC12498065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.